Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 66.64B 9.94B 8.82B 8.26B 7.48B 14.13B 958B 14.24B 99.17B 38.57B 489B 37.31B 36.51B 1,571B P/E 2026 *
50.2x
P/E 2027 * 37.9x
Enterprise Value 61.97B 9.24B 8.2B 7.68B 6.96B 13.14B 891B 13.24B 92.22B 35.87B 455B 34.69B 33.95B 1,461B EV / Sales 2026 *
7.66x
EV / Sales 2027 * 6.43x
Free-Float
62.13%
Yield 2026 *
0.72%
Yield 2027 * 0.96%
Aug. 25 CIG Shanghai Declares Interim Dividend MT
Aug. 24 CIG Shanghai's H1 Profit More Than Doubles MT
Aug. 24 Asymchem Laboratories' H1 Profit Declines 16% MT
Aug. 24 Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Jul. 31 Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6% MT
Jul. 29 Shanghai Asymchem Biotechnology Development Co., Ltd. announced that it expects to receive CNY 1.239699995 billion in funding from Asymchem Laboratories Co., Ltd., Suzhou Gao Ling Qirui Healthcare Investment, L.P. and another investor CI
Jul. 27 AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building CI
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 175.98 Yuan From 132.37 Yuan, Keeps at Buy MT
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$131.48 From HK$115.43, Keeps at Buy MT
Jun. 11 Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026 CI
May. 27 Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates CI
May. 20 Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says RE
May. 15 Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026 CI
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.94B
+1.26%-2.29%+36.97%+104.79% 1,032B
+0.73%-4.78%+35.41%+61.62% 614B
+0.35%+1.29%+15.86%+79.90% 471B
+1.72%-4.92%+59.84%+36.64% 350B
+1.67%+1.55%+22.88%+41.32% 337B
+1.30%-1.07%+12.86%+34.66% 268B
+0.28%-2.47%-6.28%+10.33% 246B
-0.09%-4.97%+36.88%+50.52% 218B
-0.28%-4.66%+26.99%+92.98% 179B
Average +0.40%-3.39%+26.82%+56.97% 412.76B
Weighted average by Cap. +0.13%-3.18%+29.82%+67.25%

Financials

2026 *2027 *
Net sales 8.09B 1.21B 1.07B 1B 908M 1.72B 116B 1.73B 12.04B 4.68B 59.33B 4.53B 4.43B 191B 9.8B 1.46B 1.3B 1.21B 1.1B 2.08B 141B 2.09B 14.59B 5.67B 71.9B 5.49B 5.37B 231B
Net income 1.41B 211M 187M 175M 159M 299M 20.3B 302M 2.1B 817M 10.35B 790M 773M 33.29B 1.82B 271M 241M 225M 204M 385M 26.13B 388M 2.7B 1.05B 13.33B 1.02B 996M 42.86B
Net Debt -4.67B -697M -619M -579M -525M -991M -67.19B -998M -6.95B -2.7B -34.28B -2.62B -2.56B -110B -3.66B -545M -484M -453M -411M -775M -52.56B -781M -5.44B -2.12B -26.81B -2.05B -2B -86.2B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Asymchem Laboratories (Tianjin) Co., Ltd.